Pooled statistical meta-analyses and systematic reviews aggregating thousands of patients across multiple randomized controlled trials to measure true effect size. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
This study provides the precise effects of metformin single-drug treatment regarding the decreases in fasting plasma glucose and glycosated hemoglobin that physician can expected in drug-naive patients with type 2 diabetes.
The findings support a growing impression that finasteride is associated with adverse psychiatric effects that can persist in association with sexual dysfunction after discontinuing finasteride treatment.
Our meta-analysis showed that serum vitamin E levels were lower in patients suffering from vitiligo, psoriasis, eczema and acne.
TRT outcomes observed in KS regarding BMD, body composition and glyco-metabolic control, are similar to those observed in male with hypogonadism not related to KS.
Selenium levels were associated with several skin diseases and the disease severity, and high selenium levels tended to be a protective factor in certain skin diseases.
The findings suggest that men with OSA have a high incidence of nocturia.
Published literature suggests a bidirectional relationship between inflammatory bowel disease and eczema.
Despite heterogeneity in exercises, myofunctional therapy decreased AHI by 43% in children, and increased mean oxygen saturations in children with mild to moderate OSA and can serve as an add-on booster OSA treatment.
Two investigators independently reviewed the articles and classified the data for meta-analysis.
The present study firstly provided quantitative information for metformin effects on weight in different disease states, including patients with type 2 diabetes, patients with antipsychotic induced weight gain, patients with...
Statin use may not be associated with a lower risk of incidence and progression of OA, regardless of joint site.
Similar to the VOYAGER meta-analysis, which reported a greater efficacy of rosuvastatin in comparison with atorvastatin and simvastatin in Caucasian patients, we found that the efficacy of rosuvastatin was superior to...
Our meta-analysis suggests that GLP-1RAs provide better glycaemic effects than SGLT-2is in patients with T2DM uncontrolled by metformin, albeit while increasing risk for hypoglycaemia and.
Our findings demonstrate that metformin is significantly associated with a decreased risk and increased survival in lung cancer.
We found a modest increase in the risk of atopic eczema within 3 years following bereavement, which peaked in the first 3 months.
This meta-analysis showed that metformin use significantly reduces colorectal adenoma and cancer incidence and improves colorectal cancer outcomes.
OS significantly increased heart and blood vessel risk including the prevalence of high blood pressure and lung high blood pressure.
JAK inhibitors appear to be effective in treating eczema.
The present study suggests that combination therapy could be an effective, safe and promising option for the treatment of AGA.
This meta-analysis reveals that statins significantly increase plasma Lp(a) levels.
Based on the effect on LDL cholesterol, pitavastatin is about 6-fold more potent than atorvastatin, 1.7-fold more potent than rosuvastatin, 77-fold more potent than fluvastatin and 3.3-fold less potent than cerivastatin.
At week 12, the pooled proportion of placebo-treated AD patients that obtained EASI50, EASI75 and EASI90 was significantly higher than the pooled proportion of placebo-treated psoriasis patients obtaining PASI50, PASI75 and...
The results indicate that OSA is one of independent risk factors of PD.
Risk of bias and imprecision limit our confidence in the evidence.
CONCLUSIONS Tadalafil and tamsulosin have similar effects in managing LUTS secondary to BPH.
Probabilistic sensitivity analysis and one-way sensitivity analyses showed the robustness of the model results.
The failure of the secondary treatment using gliflozins occurs in less than one year of treatment (less than 50% of the patients presenting HbA1c > 7 %).
Irrespective of the intervention used, complete resolution of OSA was not achieved in most trials.
Oral semaglutide can effectively and safely reduce blood glucose, body weight and systolic blood pressure.
Our meta-analysis indicated that following metformin treatment in patients with T2DM was associated with decreased heart and blood vessel risk, both with the mortality and incidence.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
